002907 华森制药
已收盘 10-30 15:00:00
资讯
新帖
简况
华森制药(002907)2026年三季报简析:营收净利润同比双双增长,应收账款上升
证券之星 · 10-28
华森制药(002907)2026年三季报简析:营收净利润同比双双增长,应收账款上升
股市必读:华森制药新发布《2026年三季度报告》
证券之星 · 10-28
股市必读:华森制药新发布《2026年三季度报告》
华森制药(002907)披露2026年三季度报告,10月26日股价下跌0.37%
证券之星 · 10-26
华森制药(002907)披露2026年三季度报告,10月26日股价下跌0.37%
华森制药(002907)9月30日股东户数3.91万户,较上期增加33.41%
证券之星 · 10-26
华森制药(002907)9月30日股东户数3.91万户,较上期增加33.41%
华森制药(002907.SZ)发布前三季度业绩,归母净利润1.01亿元,同比增长39.67%
智通财经 · 10-26
华森制药(002907.SZ)发布前三季度业绩,归母净利润1.01亿元,同比增长39.67%
异动快报:华森制药(002907)10月22日14点40分触及跌停板
证券之星 · 10-22
异动快报:华森制药(002907)10月22日14点40分触及跌停板
股市必读:华森制药新发布《关于公司获得药品注册证书的公告》
证券之星 · 10-19
股市必读:华森制药新发布《关于公司获得药品注册证书的公告》
华森制药(002907)披露获得奥利司他胶囊《药品注册证书》公告,10月16日股价上涨2.75%
证券之星 · 10-16
华森制药(002907)披露获得奥利司他胶囊《药品注册证书》公告,10月16日股价上涨2.75%
股市必读:华森制药新发布《关于公司产品完成境内生产药品备案的公告》
证券之星 · 10-08
股市必读:华森制药新发布《关于公司产品完成境内生产药品备案的公告》
华森制药(002907)9月30日主力资金净买入1986.02万元
证券之星 · 09-30
华森制药(002907)9月30日主力资金净买入1986.02万元
股市必读:华森制药新发布《关于公司获得硫酸氢氯吡格雷片药品补充申请批准通知书暨成为药品上市许可持有人的公告》
证券之星 · 09-28
股市必读:华森制药新发布《关于公司获得硫酸氢氯吡格雷片药品补充申请批准通知书暨成为药品上市许可持有人的公告》
股市必读:华森制药新发布《关于公司全资子公司受让成都华森奥睿药业有限公司股权的进展公告》
证券之星 · 09-24
股市必读:华森制药新发布《关于公司全资子公司受让成都华森奥睿药业有限公司股权的进展公告》
华森制药:9月23日召开业绩说明会,投资者参与
证券之星 · 09-23
华森制药:9月23日召开业绩说明会,投资者参与
异动快报:华森制药(002907)9月21日10点37分触及涨停板
证券之星 · 09-21
异动快报:华森制药(002907)9月21日10点37分触及涨停板
股市必读:华森制药新发布《2026年半年度权益分派实施公告》
证券之星 · 08-28
股市必读:华森制药新发布《2026年半年度权益分派实施公告》
华森制药(002907)披露收到注射用二乙酰氨乙酸乙二胺再注册批准通知书,8月26日股价上涨2.92%
证券之星 · 08-26
华森制药(002907)披露收到注射用二乙酰氨乙酸乙二胺再注册批准通知书,8月26日股价上涨2.92%
华森制药最新公告:收到药品再注册批准通知书
证券之星 · 08-25
华森制药最新公告:收到药品再注册批准通知书
华森制药(002907)2026年中报简析:净利润同比增长16.74%,盈利能力上升
证券之星 · 08-22
华森制药(002907)2026年中报简析:净利润同比增长16.74%,盈利能力上升
图解华森制药中报:第二季度单季净利润同比增长122.09%
证券之星 · 08-21
图解华森制药中报:第二季度单季净利润同比增长122.09%
华森制药(002907)披露2026年半年度报告,8月20日股价下跌6.19%
证券之星 · 08-20
华森制药(002907)披露2026年半年度报告,8月20日股价下跌6.19%
加载更多
公司概况
公司名称:
重庆华森制药股份有限公司
所属行业:
医药制造业
上市日期:
2017-10-20
主营业务:
重庆华森制药股份有限公司的主营业务是中成药、化学药的研发、生产和销售。公司的主要产品是中成药、化学药。
发行价格:
4.53
{"stockData":{"symbol":"002907","market":"SZ","secType":"STK","nameCN":"华森制药","latestPrice":13.21,"timestamp":1793343810000,"preClose":13.21,"halted":0,"volume":10404715,"delay":0,"changeRate":0,"floatShares":339000000,"shares":418000000,"eps":0.2247,"marketStatus":"已收盘","change":0,"latestTime":"10-30 15:00:00","open":13.06,"high":13.94,"low":12.81,"amount":139000000,"amplitude":0.0855,"askPrice":13.21,"askSize":18,"bidPrice":13.2,"bidSize":441,"shortable":0,"etf":0,"ttmEps":0.2247,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793583000000},"marketStatusCode":5,"adr":0,"adjPreClose":13.21,"symbolType":"stock","openAndCloseTimeList":[[1793323800000,1793331000000],[1793336400000,1793343600000]],"highLimit":14.53,"lowLimit":11.89,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":417596314,"isCdr":false,"pbRate":3.13,"roa":"--","peRate":58.789497,"roe":"5.84%","epsLYR":0.1559,"committee":0.676104,"marketValue":5516000000,"turnoverRate":0.0307,"status":2,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-11-02。","floatMarketCap":4479000000},"requestUrl":"/m/hq/s/002907","defaultTab":"news","newsList":[{"id":"2678460256","title":"华森制药(002907)2026年三季报简析:营收净利润同比双双增长,应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2678460256","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678460256?lang=zh_cn&edition=full","pubTime":"2026-10-28 20:30","pubTimestamp":1793190634,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期华森制药发布2026年三季报。截至本报告期末,公司营业总收入6.49亿元,同比上升3.7%,归母净利润1.01亿元,同比上升39.67%。按单季度数据看,第三季度营业总收入2.36亿元,同比上升28.0%,第三季度归母净利润3821.8万元,同比上升106.53%。本报告期华森制药应收账款上升,应收账款同比增幅达52.16%。本文数据来源于华森制药2026年三季报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800047569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678748958","title":"股市必读:华森制药新发布《2026年三季度报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678748958","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678748958?lang=zh_cn&edition=full","pubTime":"2026-10-28 04:59","pubTimestamp":1793134762,"startTime":"0","endTime":"0","summary":"公司公告汇总2026年三季度报告华森制药2026年第三季度营业收入为235,510,073.56元,同比增长28.00%;归属于上市公司股东的净利润为38,218,046.45元,同比增长106.53%。第四届董事会第十次会议决议公告重庆华森制药股份有限公司于2026年10月26日召开第四届董事会第十次会议,审议通过《关于公司〈2026年第三季度报告〉的议案》和《关于调整公司组织架构的议案》。董事会认为公司2026年第三季度报告内容真实、准确、完整,符合相关法律法规及信息披露规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800006385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678948231","title":"华森制药(002907)披露2026年三季度报告,10月26日股价下跌0.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678948231","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678948231?lang=zh_cn&edition=full","pubTime":"2026-10-26 22:37","pubTimestamp":1793025439,"startTime":"0","endTime":"0","summary":"截至2026年10月26日收盘,华森制药报收于13.63元,较前一交易日下跌0.37%,最新总市值为56.92亿元。该股当日开盘13.58元,最高13.78元,最低13.37元,成交额达8992.46万元,换手率为1.96%。报告显示,2026年第三季度营业收入为235,510,073.56元,同比增长28.00%;归属于上市公司股东的净利润为38,218,046.45元,同比增长106.53%。年初至报告期末营业收入为649,060,783.21元,同比增长3.70%;归属于上市公司股东的净利润为101,202,241.87元,同比增长39.67%。经营活动产生的现金流量净额为81,751,435.27元,同比增长229.74%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600037836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678169711","title":"华森制药(002907)9月30日股东户数3.91万户,较上期增加33.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678169711","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678169711?lang=zh_cn&edition=full","pubTime":"2026-10-26 17:57","pubTimestamp":1793008638,"startTime":"0","endTime":"0","summary":"证券之星消息,近日华森制药披露,截至2026年9月30日公司股东户数为3.91万户,较6月30日增加9803.0户,增幅为33.41%。在中药行业个股中,华森制药股东户数低于行业平均水平,截至9月30日,中药行业平均股东户数为5.26万户。从股价来看,2026年6月30日至2026年9月30日,华森制药区间涨幅为12.51%,在此期间股东户数增加9803.0户,增幅为33.41%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600024316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678616613","title":"华森制药(002907.SZ)发布前三季度业绩,归母净利润1.01亿元,同比增长39.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678616613","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678616613?lang=zh_cn&edition=full","pubTime":"2026-10-26 17:30","pubTimestamp":1793007017,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华森制药 发布2026年第三季度报告,公司前三季度实现营业收入6.49亿元,同比增长3.70%;归属于上市公司股东的净利润1.01亿元,同比增长39.67%;归属于上市公司股东的扣除非经常性损益的净利润8361.21万元,同比增长60.17%;基本每股收益0.2423元。2026年前三季度,归属于上市公司股东的净利润及扣除非经常性损益的净利润分别同比上升39.67%和60.17%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677163931","title":"异动快报:华森制药(002907)10月22日14点40分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2677163931","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677163931?lang=zh_cn&edition=full","pubTime":"2026-10-22 14:45","pubTimestamp":1792651533,"startTime":"0","endTime":"0","summary":"证券之星10月22日盘中消息,14点40分华森制药(002907)触及跌停板。其所属行业中药目前下跌。领涨股为恩威医药。该股为维生素,中药,新冠病毒防治概念热股。10月21日的资金流向数据方面,主力资金净流出588.64万元,占总成交额2.61%,游资资金净流入1454.9万元,占总成交额6.45%,散户资金净流出866.26万元,占总成交额3.84%。近5日资金流向一览见下表:华森制药主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200020457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676578276","title":"股市必读:华森制药新发布《关于公司获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676578276","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676578276?lang=zh_cn&edition=full","pubTime":"2026-10-19 02:04","pubTimestamp":1792346652,"startTime":"0","endTime":"0","summary":"截至2026年10月16日收盘,华森制药报收于14.58元,上涨2.75%,换手率4.8%,成交量16.27万手,成交额2.41亿元。公司公告汇总:公司获得奥利司他胶囊《药品注册证书》,获批按甲类非处方药管理,有效期至2031年10月12日。该药品为化学药品4类,上市许可持有人和生产企业均为公司本身,有效期至2031年10月12日。奥利司他胶囊为国内目前唯一获批用于成人肥胖或超重治疗的口服非处方药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900000631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675518309","title":"华森制药(002907)披露获得奥利司他胶囊《药品注册证书》公告,10月16日股价上涨2.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675518309","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675518309?lang=zh_cn&edition=full","pubTime":"2026-10-16 22:33","pubTimestamp":1792161213,"startTime":"0","endTime":"0","summary":"截至2026年10月16日收盘,华森制药报收于14.58元,较前一交易日上涨2.75%,最新总市值为60.89亿元。近日,重庆华森制药股份有限公司收到国家药监局核准签发的奥利司他胶囊的《药品注册证书》,批准注册并同意按(甲类)非处方药管理。该药品为化学药品4类,上市许可持有人和生产企业均为公司本身,有效期至2031年10月12日。奥利司他胶囊为国内目前唯一获批用于成人肥胖或超重治疗的口服非处方药,市场需求较大,但市场竞争较为充分。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600040527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673146060","title":"股市必读:华森制药新发布《关于公司产品完成境内生产药品备案的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673146060","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673146060?lang=zh_cn&edition=full","pubTime":"2026-10-08 01:01","pubTimestamp":1791392474,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘,华森制药报收于14.9元,上涨3.33%,换手率4.86%,成交量16.48万手,成交额2.45亿元。当日关注点交易信息汇总:9月30日主力资金净流入1986.02万元,占总成交额8.1%。公司公告汇总:苍耳子鼻炎胶囊药品有效期由24个月延长至36个月,备案号渝备2026027598,上市许可持有人及生产企业均为华森制药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800000702.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671276716","title":"华森制药(002907)9月30日主力资金净买入1986.02万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671276716","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671276716?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:28","pubTimestamp":1790753312,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年9月30日收盘,华森制药报收于14.9元,上涨3.33%,换手率4.86%,成交量16.48万手,成交额2.45亿元。华森制药主营业务:公司是一家集药品研发、生产、销售于一体的综合型制药企业,业态覆盖医药工业、医药商业及医药零售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000019038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670401662","title":"股市必读:华森制药新发布《关于公司获得硫酸氢氯吡格雷片药品补充申请批准通知书暨成为药品上市许可持有人的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670401662","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670401662?lang=zh_cn&edition=full","pubTime":"2026-09-28 03:18","pubTimestamp":1790536692,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘,华森制药报收于14.43元,下跌1.9%,换手率2.2%,成交量7.47万手,成交额1.09亿元。交易信息汇总资金流向9月24日主力资金净流出130.47万元,占总成交额1.2%;游资资金净流出312.58万元,占总成交额2.87%;散户资金净流入443.05万元,占总成交额4.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669314438","title":"股市必读:华森制药新发布《关于公司全资子公司受让成都华森奥睿药业有限公司股权的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669314438","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669314438?lang=zh_cn&edition=full","pubTime":"2026-09-24 00:59","pubTimestamp":1790182747,"startTime":"0","endTime":"0","summary":"公司公告汇总关于公司全资子公司受让成都华森奥睿药业有限公司股权的进展公告重庆华森制药股份有限公司全资子公司重庆华森英诺生物科技有限公司于2025年5月签署《股权变更协议》,无偿受让成都华森奥睿药业有限公司37.3619%股权,作为对公司及子公司承担A轮投资人回购义务的补偿。因协议生效后12个月内未完成股权置换,触发回购条款。回购完成后,公司及子公司合计持有目标公司74.6956%股权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400001816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669826424","title":"华森制药:9月23日召开业绩说明会,投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2669826424","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669826424?lang=zh_cn&edition=full","pubTime":"2026-09-23 23:01","pubTimestamp":1790175691,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年9月23日华森制药发布公告称公司于2026年9月23日召开业绩说明会。至于高壁垒仿制药,公司则遵循财务投资逻辑,重点考察生产成本控制能力、集采中标概率及预期利润率。华森制药主营业务:公司是一家集药品研发、生产、销售于一体的综合型制药企业,业态覆盖医药工业、医药商业及医药零售。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300041673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669413180","title":"异动快报:华森制药(002907)9月21日10点37分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2669413180","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669413180?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:41","pubTimestamp":1789958466,"startTime":"0","endTime":"0","summary":"证券之星9月21日盘中消息,10点37分华森制药(002907)触及涨停板。其所属行业中药目前上涨。领涨股为精华制药。该股为创新药,减肥药,医药概念热股,当日创新药概念上涨4.25%,减肥药概念上涨4.01%,医药概念上涨3.68%。9月18日的资金流向数据方面,主力资金净流出371.72万元,占总成交额3.38%,游资资金净流入159.36万元,占总成交额1.45%,散户资金净流入212.36万元,占总成交额1.93%。近5日资金流向一览见下表:华森制药主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100006825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662035555","title":"股市必读:华森制药新发布《2026年半年度权益分派实施公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662035555","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662035555?lang=zh_cn&edition=full","pubTime":"2026-08-28 05:03","pubTimestamp":1787864596,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘,华森制药报收于16.32元,上涨0.74%,换手率10.3%,成交量34.92万手,成交额5.68亿元。公司公告汇总:华森制药披露2026年半年度权益分派方案,以总股本417,596,314股为基数,每10股派发现金红利0.35元(含税),股权登记日为2026年9月3日,除权除息日为2026年9月4日。交易信息汇总资金流向8月27日主力资金净流出405.82万元,占总成交额0.71%;游资资金净流出3415.9万元,占总成交额6.02%;散户资金净流入3821.72万元,占总成交额6.73%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800009514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662679481","title":"华森制药(002907)披露收到注射用二乙酰氨乙酸乙二胺再注册批准通知书,8月26日股价上涨2.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662679481","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662679481?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:27","pubTimestamp":1787736474,"startTime":"0","endTime":"0","summary":"截至2026年8月26日收盘,华森制药报收于16.2元,较前一交易日上涨2.92%,最新总市值为67.65亿元。该股当日开盘15.88元,最高17.3元,最低15.88元,成交额达7.13亿元,换手率为12.82%。华森制药于近日收到重庆市药品监督管理局核准签发的关于注射用二乙酰氨乙酸乙二胺的《药品再注册批准通知书》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600038751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662782046","title":"华森制药最新公告:收到药品再注册批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2662782046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662782046?lang=zh_cn&edition=full","pubTime":"2026-08-25 16:41","pubTimestamp":1787647300,"startTime":"0","endTime":"0","summary":"华森制药(002907.SZ)公告称,公司近日收到重庆市药品监督管理局核准签发的关于产品注射用二乙酰氨乙酸乙二胺(0.2g和0.4g)的《药品再注册批准通知书》。该药品适用于预防和治疗各种原因出血。本次获得再注册批准将确保药品正常生产和销售,短期内不会对公司经营业绩产生重大影响。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500033873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661550218","title":"华森制药(002907)2026年中报简析:净利润同比增长16.74%,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2661550218","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661550218?lang=zh_cn&edition=full","pubTime":"2026-08-22 06:13","pubTimestamp":1787350439,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期华森制药发布2026年中报。截至本报告期末,公司营业总收入4.14亿元,同比下降6.42%,归母净利润6298.42万元,同比上升16.74%。按单季度数据看,第二季度营业总收入2.02亿元,同比下降0.62%,第二季度归母净利润3019.34万元,同比上升122.09%。本报告期华森制药盈利能力上升,毛利率同比增幅0.88%,净利率同比增幅14.35%。本文数据来源于华森制药2026年中报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200005172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661239142","title":"图解华森制药中报:第二季度单季净利润同比增长122.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661239142","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661239142?lang=zh_cn&edition=full","pubTime":"2026-08-21 01:45","pubTimestamp":1787247903,"startTime":"0","endTime":"0","summary":"证券之星消息,华森制药2026年中报显示,上半年度公司主营收入4.14亿元,同比下降6.42%;归母净利润6298.42万元,同比上升16.74%;扣非净利润5642.18万元,同比上升20.68%;其中2026年第二季度,公司单季度主营收入2.02亿元,同比下降0.62%;单季度归母净利润3019.34万元,同比上升122.09%;单季度扣非净利润2738.96万元,同比上升201.4%;负债率14.77%,投资收益173.46万元,财务费用-283.21万元,毛利率59.26%。财报数据概要请见下图:本文数据来源于华森制药2026年中报,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100001314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660280008","title":"华森制药(002907)披露2026年半年度报告,8月20日股价下跌6.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660280008","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660280008?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:16","pubTimestamp":1787235376,"startTime":"0","endTime":"0","summary":"截至2026年8月20日收盘,华森制药报收于15.15元,较前一交易日下跌6.19%,最新总市值为63.27亿元。该股当日开盘16.26元,最高16.41元,最低14.8元,成交额达4.75亿元,换手率为9.14%。近日,华森制药披露2026年半年度报告。报告显示,报告期内营业收入为413,550,709.65元,同比下降6.42%;归属于上市公司股东的净利润为62,984,195.42元,同比增长16.74%;扣除非经常性损益后的净利润为56,421,793.99元,同比增长20.68%。经营活动产生的现金流量净额为54,661,543.27元,同比增长98.58%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000045220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793512695551,"stockEarnings":[{"period":"1week","weight":-0.0344},{"period":"1month","weight":-0.1134},{"period":"3month","weight":0.0378},{"period":"6month","weight":-0.0477},{"period":"1year","weight":-0.1707},{"period":"ytd","weight":-0.1029}],"compareEarnings":[{"period":"1week","weight":-0.0248},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0609},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.0973},{"period":"ytd","weight":-0.0932}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆华森制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"39147人(较上一季度增加33.41%)","perCapita":"8660股","listingDate":"2017-10-20","address":"重庆市荣昌区工业园区","registeredCapital":"41759万元","survey":" 重庆华森制药股份有限公司的主营业务是中成药、化学药的研发、生产和销售。公司的主要产品是中成药、化学药。","listedPrice":4.53},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华森制药(002907)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华森制药(002907)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华森制药,002907,华森制药股票,华森制药股票老虎,华森制药股票老虎国际,华森制药行情,华森制药股票行情,华森制药股价,华森制药股市,华森制药股票价格,华森制药股票交易,华森制药股票购买,华森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华森制药(002907)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华森制药(002907)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}